Skip to main content
. 2023 Mar 9;7(13):3284–3296. doi: 10.1182/bloodadvances.2022009391

Table 4.

Multivariate analysis for OS and CIR (censored for SCT)

Covariate OS
CIR
HR (95% confidence interval) P value HR (95% confidence interval) P value
Model for all patients
 Age, continuous, y 1.02 (1.00-1.03) .025 0.99 (0.97-1.01) .204
 Treatment cohort
 IA Reference Reference
 LOW + VEN 1.06 (0.70-1.61) .786 0.90 (0.57-1.43) .668
 Best response
 CR Reference Reference
 CRi 1.50 (1.03-2.17) .033 1.97 (1.32-2.95) .001
 MLFS 2.66 (1.59-4.46) <.001 1.84 (0.79-4.26) .156
 MRD status
 Negative Reference Reference
 Positive 1.53 (1.13-2.08) .006 1.69 (1.23-2.34) .001
 ELN 2017 risk
 Favorable Reference Reference
 Intermediate 1.34 (0.89-2.02) .163 1.92 (1.25-2.94) .003
 Adverse 1.96 (1.32-2.92) .001 2.75 (1.78-4.24) < .001
Model for patients ≥60 y
 Age, continuous, y 1.01 (0.98-1.04) .435 0.99 (0.95-1.03) .551
 Treatment cohort
 IA Reference Reference
 LOW + VEN 1.33 (0.73-2.44) .350 1.30 (0.65-2.59) .460
 Best response
 CR Reference Reference
 CRi 1.50 (0.93-2.43) .094 1.96 (1.19-3.24) .009
 MLFS 4.08 (2.14-7.75) <.001 1.36 (0.48-3.81) .560
 MRD status
 Negative Reference Reference
 Positive 1.43 (0.95-2.14) .086 1.73 (1.09-2.75) .020
 ELN 2017 risk
 Favorable Reference Reference
 Intermediate 1.43 (0.78-2.63) .248 2.20 (1.08-4.50) .030
 Adverse 1.88 (1.12-3.14) .016 2.66 (1.43-4.96) .002